{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:28:08Z","timestamp":1791908888580,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.copbio.2004.09.001","type":"journal-article","created":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T11:21:27Z","timestamp":1097839287000},"page":"506-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?"],"prefix":"10.1016","volume":"15","author":[{"given":"Ingo","family":"Drexler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Staib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2004.09.001_bib1","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2004.09.001_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.copbio.2004.09.001_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nbt845","article-title":"Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors","volume":"21","author":"Vasilakis","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.copbio.2004.09.001_bib4","first-page":"77","article-title":"Construction and isolation of recombinant MVA","volume":"269","author":"Staib","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.copbio.2004.09.001_bib5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2144\/03344bm02","article-title":"Improved host range selection for recombinant modified vaccinia virus Ankara","volume":"34","author":"Staib","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.copbio.2004.09.001_bib6","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1128\/JVI.77.15.8394-8407.2003","article-title":"Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L","volume":"77","author":"Hornemann","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2004.09.001_bib8_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1073\/pnas.262668999","article-title":"Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T-cells and comparative analysis of smallpox vaccines","volume":"100","author":"Drexler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2004.09.001_bib9","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2004.09.001_bib10_1","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2004.09.001_bib11_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2004.09.001_bib12","first-page":"4955","article-title":"Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo","volume":"59","author":"Drexler","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2004.09.001_bib13_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2004.09.001_bib14_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.copbio.2004.09.001_bib15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1089\/104303403322319426","article-title":"Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial","volume":"14","author":"Di Nicola","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.copbio.2004.09.001_bib16","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib17","first-page":"406","article-title":"Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus","volume":"11","author":"Cosma","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib18","first-page":"243","article-title":"Monitoring of human immunological responses to vaccinia virus","volume":"269","author":"Harrop","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.copbio.2004.09.001_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-1759(02)00025-X","article-title":"Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining","volume":"262","author":"Speller","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.copbio.2004.09.001_bib20","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.76.7.3329-3337.2002","article-title":"Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope","volume":"76","author":"Harrington","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib21","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.76.15.7713-7723.2002","article-title":"Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara","volume":"76","author":"Ober","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib22_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1084\/jem.20022222","article-title":"Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses","volume":"197","author":"Terajima","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.copbio.2004.09.001_bib23","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.74.16.7651-7655.2000","article-title":"Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector","volume":"74","author":"Ramirez","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib24","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1128\/JVI.77.12.7048-7057.2003","article-title":"Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes","volume":"77","author":"Gherardi","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib25","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","article-title":"Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib27","first-page":"7942","article-title":"Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses","volume":"63","author":"Hodge","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2004.09.001_bib28","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.4049\/jimmunol.172.5.3094","article-title":"Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus","volume":"172","author":"Anderson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1099\/vir.0.18738-0","article-title":"Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine","volume":"84","author":"Hanke","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib30","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.78.8.3930-3940.2004","article-title":"Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib31","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.76.15.7625-7631.2002","article-title":"Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA\/MVA vaccines","volume":"76","author":"Amara","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib32","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.4049\/jimmunol.169.8.4511","article-title":"Differences between T cell epitopes recognized after immunization and after infection","volume":"169","author":"Vogel","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib33","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/JVI.77.4.2400-2409.2003","article-title":"Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system","volume":"77","author":"Evans","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2001.1345","article-title":"Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model","volume":"294","author":"Earl","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.copbio.2004.09.001_bib35","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.4049\/jimmunol.172.10.6209","article-title":"Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule","volume":"172","author":"Gherardi","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib36","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.4049\/jimmunol.170.5.2599","article-title":"Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias","volume":"170","author":"Woodberry","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/vir.0.19701-0","article-title":"A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans","volume":"85","author":"Mwau","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.292.5514.69","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.copbio.2004.09.001_bib39","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1128\/JVI.76.8.4108-4112.2002","article-title":"Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication","volume":"76","author":"Allen","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib40","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1128\/JVI.76.14.7187-7202.2002","volume":"76","author":"Horton","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib41","doi-asserted-by":"crossref","first-page":"13348","DOI":"10.1128\/JVI.77.24.13348-13360.2003","article-title":"Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239","volume":"77","author":"Vogel","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib42","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1099\/vir.0.79794-0","article-title":"Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge","volume":"85","author":"Negri","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib43","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.4049\/jimmunol.172.6.3745","article-title":"Control of simian\/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates","volume":"172","author":"Bertley","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib44_1","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.copbio.2004.09.001_bib45_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2003-10-3469","article-title":"Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.copbio.2004.09.001_bib46","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.4049\/jimmunol.172.4.2256","article-title":"Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection","volume":"172","author":"Gibson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib47","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1086\/344234","article-title":"Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone","volume":"186","author":"Meseda","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.copbio.2004.09.001_bib48","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib49_1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/104303402753812520","article-title":"Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus","volume":"13","author":"Corona Gutierrez","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.copbio.2004.09.001_bib50","first-page":"1129","article-title":"Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors","volume":"1","author":"Mulryan","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.copbio.2004.09.001_bib51","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.4049\/jimmunol.170.6.3401","article-title":"CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model","volume":"170","author":"Espenschied","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J Gene Med"},{"key":"10.1016\/j.copbio.2004.09.001_bib53","doi-asserted-by":"crossref","first-page":"11859","DOI":"10.1128\/JVI.77.21.11859-11866.2003","article-title":"Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii","volume":"77","author":"Gonzalez-Aseguinolaza","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.copbio.2004.09.001_bib54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/378515","article-title":"Safety and immunogenicity of DNA\/modified vaccinia virus Ankara malaria vaccination in African adults","volume":"188","author":"Moorthy","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.copbio.2004.09.001_bib55","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/IAI.70.3.1623-1626.2002","article-title":"Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8+- and CD4+-T-cell epitopes from antigen 85A","volume":"70","author":"McShane","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.copbio.2004.09.001_bib56","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.copbio.2004.09.001_bib57_1","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-04-0602","article-title":"Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma","volume":"10","author":"Di Nicola","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166904001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166904001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:31:17Z","timestamp":1760689877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166904001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0958166904001314"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2004.09.001","relation":{},"ISSN":["0958-1669"],"issn-type":[{"value":"0958-1669","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2004.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}